Datopotamab Deruxtecan for neoplasm metastasis

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 16 May 2022: Trial registered, NCT05374512
  2. 16 May 2022: Trial started, NCT05374512

The trials

NCT05374512: A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

State
Under way
Phase
Phase 3
People
644 taking part
Started
16 May 2022
Primary completion
25 Aug 2025
Arms
Dato-DXd
Results
None posted
  1. 16 May 2022: Trial registered
  2. 16 May 2022: Trial started

NCT06508216: A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast Cancer

State
Under way
Phase
Phase 1 and Phase 2
People
50 planned
Started
5 Jul 2024
Primary completion
17 Dec 2025
Arms
Module 1 of part 2 : Datopotamab Deruxtecan (Dato-DXd) Monotherapy
Results
None posted
  1. 5 Jul 2024: Trial started
  2. 18 Jul 2024: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.